The arrival of RNA, cell and gene and other Advanced Therapy Medicinal Products (ATMPs) as powerful new therapeutic tools has important implications for life science companies, for healthcare systems and for patients. For life science companies, they bring new ways of designing and building drugs, often in close collaboration with healthcare systems. With over 3500 of these novel medicines currently at various stages of evaluation, they can also be expected to play an increasingly important and high-value role in their future product portfolios. For patients, they bring the potential of treatments, and in some cases cures for diseases and conditions for which therapeutic options were previously limited or unavailable. 

Although these new medicines show enormous promise, a number of important challenges will need to be addressed before their full potential can be realised. Pressure to reduce production costs will increase as demand grows and as more drugs for more indications reach the market in the years ahead. Already facing a ‘manufacturing crunch’ and supply chain constraints, life science companies will need to devise radical new ways to manufacture these novel modalities - driving cost efficiencies, improving process development, ensuring scalability and driving innovation in delivery, storage and yields. 

This Financial Times event, organised in partnership with Cytiva, brought together pharma, biotech, CDMOs, industry suppliers of services and equipment, and other players engaged in the fast-growing field of RNA, Cell and Gene, ATMPs manufacture and commercialisation. The focus was on innovative ways to expedite and improve biomanufacturing and ensure the next generation of advanced therapies can reach patients affordably and at scale.

Premier Digital Events Supported by the World's Best Journalism

Using leading digital technology, we have now taken our content, global audience reach and engagement to a new level through a series of unmissable virtual events. Our compelling events are chaired by respected FT journalists, feature the most senior and thought-provoking decision-makers in business, finance and politics, all accessible from your office or home.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice